Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-10-17Clinical Trial Update: A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
The randomized study comparing cystoscopy with urethral dilatation versus cystoscopy alone in women with Overactive Bladder and impaired voi…
-
CLINICAL_TRIALS research · 2016-10-11Clinical Trial Update: Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB) [EARLY_Phase 1]
This clinical trial update describes an early Phase 1 study evaluating sacral neuromodulation for refractory overactive bladder, sponsored b…
-
CLINICAL_TRIALS trial_result · 2016-09-26Clinical Trial Update: A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) [Phase 1]
Phase 1 pharmacokinetic/pharmacodynamic study of vibegron (MK-4618) in women with overactive bladder was terminated; results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-09-22Clinical Trial Update: Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
A completed Korea-based clinical trial evaluated the safety and efficacy of botulinum toxin type A (BOTOX) for urinary incontinence due to n…
-
FDA approval · 2016-09-19FDA Approved: DARIFENACIN — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original application for darifenacin (generic) by Rising Pharma Holdings, Inc. for the treatment of overactive bladder.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-09-13Clinical Trial Update: A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics
The completed study evaluated quality of life in patients switched from other antimuscarinics to solifenacin for overactive bladder.
-
CLINICAL_TRIALS trial_result · 2016-09-02Clinical Trial Update: Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
This clinical trial update reports urinary retention rates observed in real-world practice after treatment with onabotulinumtoxinA for idiop…
-
FDA approval · 2016-09-01FDA Approved: DARIFENACIN — Original Application (Cipla USA Inc.)
FDA approved the original ANDA for Darifenacin (darifenacin hydrobromide) from Cipla USA Inc., establishing a generic option for the treatme…
-
CLINICAL_TRIALS trial_result · 2016-08-30Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of Mirabegron compared with Solifenacin in adults with overactive bladder who were unsati…
-
CLINICAL_TRIALS research · 2016-08-30Clinical Trial Update: OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER [Phase 3]
Phase 3 trial comparing onabotulinumtoxinA with oral oxybutynin ER for overactive bladder; current status is unknown.
-
FDA approval · 2016-08-23FDA Approved: TROSPIUM CHLORIDE — Original Application (CIPLA USA INC.,)
The FDA approved Cipla USA's generic Trospium chloride via an Original Abbreviated New Drug Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2016-08-19Clinical Trial Update: A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers [Phase 1]
Phase 1 study evaluating how food affects exposure to fesoterodine fumarate and the pharmacokinetics of its active metabolite 5-Hydroxymethy…
-
FDA label_change · 2016-08-16FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for MYRBETRIQ (mirabegron) submitted by Astellas Pharma US, Inc., resulting in a label change for th…
-
CLINICAL_TRIALS trial_result · 2016-08-09Clinical Trial Update: A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) [Phase 1]
Phase 1 pharmacokinetics study assessing vibegron (MK-4618) in participants with renal insufficiency to understand dosing considerations.
-
FDA approval · 2016-08-01FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for MYRBETRIQ (mirabegron) by Astellas Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2016-07-21Clinical Trial Update: A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients [Phase 4]
Phase 4 safety and efficacy study evaluating botulinum toxin type A (BOTOX) for urinary incontinence due to neurogenic detrusor overactivity…
-
CLINICAL_TRIALS trial_result · 2016-07-20Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder [Phase 3]
This is a Phase 3 clinical trial update evaluating DR-3001 for efficacy and safety in women with overactive bladder. The study, sponsored by…
-
CLINICAL_TRIALS trial_result · 2016-07-19Clinical Trial Update: Tetra-NIRS Clinical Study [Phase 4]
A Phase 4 trial of the Tetra-NIRS device by Laborie Medical Technologies for lower urinary tract symptoms and overactive bladder was termina…
-
CLINICAL_TRIALS trial_result · 2016-07-12Clinical Trial Update: The Effect of Anticholinergics on Cognitive Function in the Elderly [Phase 4]
A Phase 4 trial evaluating the effect of anticholinergic drugs on cognitive function in elderly participants. The study addresses overactive…
-
CLINICAL_TRIALS research · 2016-07-01Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects [Phase 1]
This document reports a Phase 1 clinical trial to assess safety, tolerability, and pharmacokinetics of DA-8010 in healthy subjects for overa…
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers [Phase 1]
A Phase 1 study evaluated the impact of food on the pharmacokinetics of JLP-1207 in healthy male volunteers; the trial sponsored by Jeil Pha…
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. [Phase 1]
This is a Phase 1 pharmacokinetic study of JLP-1207 alone and in combination with solifenacin and tamsulosin in healthy male volunteers. The…
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin [Phase 1]
A Phase 1 pharmacokinetic study evaluating potential drug interaction between solifenacin and tamsulosin has been completed. The study was s…
-
CLINICAL_TRIALS trial_result · 2016-06-22Clinical Trial Update: A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) [Phase 1]
Phase 1 pharmacokinetic study evaluating single-dose Vibegron (MK-4618) in adults with hepatic insufficiency completed; results posted.
-
CLINICAL_TRIALS trial_result · 2016-06-17Clinical Trial Update: A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) [Phase 2]
Phase 2 study results evaluating the efficacy and safety of Vibegron (MK-4618) in adults with overactive bladder.